Introduction
============

The lipid emulsions generally used in the parenteral nutrition of critically ill patients are rich in long-chain triglycerides (LCT), especially linoleic acid (polyunsaturated series 6 fatty acid; PUFA n-6, 18:2 n-6). These preparations guarantee an optimal energy supply and prevent deficiency in essential fatty acids\[[@B1]\]. These fatty acids, aside from producing adverse metabolic effects (transitory hyperlipidemias), can alter pulmonary gas exchange due to their potentially proinflammatory properties \[[@B2]\].

The MCT/LCT emulsions are oxidized faster and provide fewer amounts of PUFAs than a LCT emulsions. While MCT emulsions do not interfere with eicosanoids synthesis, it has been considered as neutral. Thus MCT/LCT emulsions have been associated with a lower risk of lipid peroxidation and fewer alterations of membrane structures\[[@B3]\].

Polyunsaturated fatty acids of the n-3 series (PUFA n-3) are precursors of biologically active substances, e.g. the series 3 and 5 eicosanoids. These molecules use the same metabolic routes and compete for the same elongases and desaturases as linoleic and arachidonic, but ultimately they are mediators that have a much less active biological profile than linoleic acid derivatives\[[@B4]\]. In 146 patients with ARDS treated with an enteral diet rich in eicosapentaenoic acid, γ-linolenic, and antioxidants, an improved PaO~2~/FiO~2~ratio, and a reduction in pulmonary inflammatory response, frequency of new organ failures, days of mechanical ventilation and long of stay in intensive care were observed\[[@B5]\]. In 100 patients with acute pulmonary injury receiving a similar enteral diet, oxygenation was better, pulmonary compliance improved, and there was less need for mechanical ventilation\[[@B6]\]. The administration of LCT emulsions has been associated with changes in pulmonary function that depend on pulmonary disease, dose, duration, and speed of administration, and kind of infused lipids \[[@B7],[@B8]\].

Many patients with ARDS require sedoanalgesia and myorelaxation, inducing intestinal ileus and making intolerance to enteral nutrition. We hypothesized that adding n-3 to a MCT/LCT emulsion used in parenteral nutrition, should be beneficial because of the reduced amount of PUFA, would be less toxic than a lipid emulsion based on soybean oil, and that the addition of fish oil would be protective because of its anti-inflammatory properties\[[@B4]\]. The present study evaluated the hemodynamic changes and variations in pulmonary gas exchange that occurred in patients with ARDS given an intravenous lipid emulsion enriched with n-3 fatty acids.

Materials and methods
=====================

Patients
--------

We studied 16 consecutive patients with ARDS in the first 48 hours of admission and intolerance of enteral nutrition defined by gastric aspirates higher than 300 ml. Patients were enrolled after approval of the study by the Committee of Clinical Trials of the Vall d\'Hebron General University Hospital of Barcelona. All the patients or their representatives signed an informed consent before enrollment in the study. The inclusion criteria were: bilateral pulmonary infiltrates of sudden onset in the chest radiograph, PaO~2~/FiO~2~less than 200, and pulmonary capillary pressure less than 18 mm Hg\[[@B9]\]. Table [1](#T1){ref-type="table"} shows the clinical characteristics of the patients studied. Patients were excluded for age younger than 18 or older than 85 years, pregnancy, liver failure, HIV positivity, leukopenia (\< 3500 mm^3^), thrombocytopenia (\< 100,000 mm^3^), severe renal insufficiency (creatinine \> 6 mg/dl) or need for renal dialysis, signs of heart failure, transplantation, multiple blood transfusions, participation in other clinical trials simultaneously or in the last 60 days, treatment with nitrous oxide or corticoids (prednisolone 2 mg/kg/d or equivalent), multiple organ failure, severe dyslipidemia, or propofol treatment.

###### 

Clinical characteristics of patients

  **Diagnosis**                **Sex**      **Age**       **PaO~2~/FiO~2~**   **LIS**         **APACHEII**     **PEEP**         **Outcome**
  ---------------------------- ------------ ------------- ------------------- --------------- ---------------- ---------------- -------------
  **Group A: n-3**                                                                                                              
                                                                                                                                
  1\. Pneumonia                M            74            98                  4               18               7                D
                                                                                                                                
  2\. Pneumonia                M            48            166                 2.3             17               8                D
                                                                                                                                
  3\. Pneumonia                M            64            133                 3.6             18               12               D
                                                                                                                                
  4\. Sepsis                   M            50            189                 3               15               10               L
                                                                                                                                
  5\. Smoke aspiration         M            40            132                 3               16               11               L
                                                                                                                                
  6\. Bronchoaspiration        M            72            84                  2.6             21               8                D
                                                                                                                                
  7\. Mediastinitis            M            70            147                 3.3             19               10               L
                                                                                                                                
  8\. Bronchoaspiration        M            36            183                 2.5             15               7                L
                                                                                                                                
  **Total Group A:**           **8 M**      **56 ± 15**   **141 ± 37**        **3 ± 0.5**     **17.4 ± 2.1**   **9.1 ± 1.9**    **4D/4L**
                                                                                                                                
  **Group B: LCT**                                                                                                              
                                                                                                                                
  1\. Pancreatitis             F            52            152                 3               16               11               L
                                                                                                                                
  2\. Bronchoaspiration        M            57            198                 4               21               15               L
                                                                                                                                
  3\. Bronchoaspiration        M            56            177                 2.6             17               9                D
                                                                                                                                
  4\. Status postpneumectomy   M            63            60                  4               19               10               L
                                                                                                                                
  5\. Pneumonia                M            71            181                 3               18               10               L
                                                                                                                                
  6\. Pneumonia                M            43            186                 3.3             14               8                L
                                                                                                                                
  7\. Pneumonia                M            53            153                 3               19               10               D
                                                                                                                                
  8\. Pneumonia                F            81            157                 3               22               9                L
                                                                                                                                
  **Total Group B**            **6M/2F**    **59 ± 12**   **158 ± 43**        **3.2 ± 0.5**   **18.2 ± 2.6**   **10.3 ± 2.1**   **2D/6L**
                                                                                                                                
  **Total n:16**               **14M/2F**   **58 ± 13**   **149 ± 40**        **3.1 ± 0.5**   **17.8 ± 2.3**   **9.7 ± 2**      **6D/10L**

LIS: Lung Injury Score. APACHEII: Acute Physiology and Chronic Health Evaluation. PEEP: Positive End Expiratory Pressure. M: male. F: female. D: dead. L: alive.

Patients were sedated with morphine and midazolam and muscular relaxation was used as needed. All patients were ventilated mechanically (Mallinckrodt Puritan Bennett 7200 series, Carlsbad, CA, USA). Monitorization included continuous electrocardiography (ECG), heart rate (HR), pulse oximetry (SpO~2~), invasive blood pressure, pulmonary artery catheterization, and continuous cardiac output by thermodilution.

Measurements
------------

A central venous catheter was inserted to administer the lipid emulsions. The basic parameters of pulmonary mechanics were monitored with the respirator and external monitoring. Cardiac output (CO) was measured by thermodilution. Systemic blood pressure (SBP), central venous pressure (CVP), pulmonary artery pressure (PAP), and pulmonary capillary pressure (PCP) were monitored by transducers placed on the middle anteroposterior chest, zeroed to atmospheric pressure, and calibrated electronically. Systemic (SVR) and pulmonary (PVR) vascular resistance, O~2~transport (DO~2~), and pulmonary Q~s~/Q~t~were calculated with the usual formulas. Blood samples were drawn under anaerobic conditions through catheters placed in the radial artery and pulmonary artery. Oxygen (PaO~2~) and carbon dioxide (PaCO~2~) partial pressure, pH, and the concentration and mixed arterial and venous saturation of haemoglobin were measured using standard electrodes.

Study design
------------

In the first 48 hours after the diagnosis of ARDS and before receiving artificial nutrition, patients were randomized into two different groups: Group A (n = 8) received the study emulsion Lipoplus^®^20%, B.Braun Medical (50% MCT, 40% LCT, 10% ω-3); Group B (n = 8) received the control emulsion Intralipid^®^20% Fresenius Kabi (100% LCT). The lipid emulsions were administered during 12 hours at a rate of 0.12 g/kg/h. During the lipid perfusion no recruitment maneuvres were done.

Measurements were made at baseline (immediately before the administration of lipid emulsions, every hour during the lipid infusion, at the end of lipid perfusion and six hours latter. Data reported in tables: baseline (t 0), six hours of perfusion (t 6); end of perfusion (t 12), and six hours after perfusion (t 18). Basic parameters of pulmonary mechanics, arterial and mixed venous gas analysis, hemodynamic parameters, and oxygen transport were measured at all stages.

Statistical analysis
--------------------

The data were imported from Access databases to SPSS. The following statistical parameters were calculated for numerical variables: mean and standard desviation. Differences in the means were analyzed by the T-test. Differences in time of the different parameters studied, depending on the type of emulsion, were assessed by repeated-measure analysis of variance (ANOVA). The level of statistical significance was defined as p \< 0.05.

Results
=======

Characteristics of the study population
---------------------------------------

At baseline, the groups were comparable (table [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Probably because of the exclusion criteria, the majority of the patients studied are patients with primary pulmonary disease as primary etiology of the ARDS. Although mortality was 50% in group A and 25% in group B, no significant differences in survival between the two groups were found. Probably the differences in mortality between groups are a simple size question. The global mortality rate in the ICU during the study period time was 22%; in this ICU no patients with coronary disease or cardiovascular surgery were admitted. All patients were sedated with midazolam and morphine in continuous perfusion and underwent controlled-volume ventilation. No significant modifications in the ventilation parameters were necessary during the study period time. There were no significant changes between the two groups.

###### 

Hemodynamic parameters

                    **T-0 h (baseline, preinfusion)**   **T-6 h**     **T-12 h (final infusion)**   **T-18 h (6 h postinfusion)**
  ----------------- ----------------------------------- ------------- ----------------------------- -------------------------------
  **HR**                                                                                            
                                                                                                    
  A: n-3            91 ± 19                             101 ± 20      100 ± 21                      91 ± 25
                                                                                                    
  B: LCT            95 ± 13                             93 ± 12       95 ± 12                       84 ± 16
                                                                                                    
  **CO**                                                                                            
                                                                                                    
  A: n-3            7.8 ± 2.8                           8.4 ± 2.7     8.5 ± 2.7                     7.8 ± 3
                                                                                                    
  B: LCT            6.9 ± 1.3                           7.3 ± 1.9     6.8 ± 1.6                     6.1 ± 1.3
                                                                                                    
  **SAP**                                                                                           
                                                                                                    
  A: n-3            127 ± 19                            113 ± 14      117 ± 15                      131 ± 24
                                                                                                    
  B: LCT            126 ± 9                             126 ± 10      124 ± 14                      121 ± 14
                                                                                                    
  **MPAP**                                                                                          
                                                                                                    
  A: n-3            26 ± 5                              29 ± 4        28 ± 7                        28 ± 6
                                                                                                    
  B: LCT            30 ± 7                              31 ± 7        31 ± 6                        28 ± 7
                                                                                                    
  **PW**                                                                                            
                                                                                                    
  A: n-3            13 ± 4\*                            13 ± 2        14 ± 3                        14 ± 4
                                                                                                    
  B: LCT            16 ± 2                              17 ± 2        17 ± 2                        16 ± 2
                                                                                                    
  **PVR**                                                                                           
                                                                                                    
  A: n-3            162 ± 122                           187 ± 98      155 ± 68                      162 ± 92
                                                                                                    
  B: LCT            147 ± 84                            142 ± 102     138 ± 79                      134 ± 77
                                                                                                    
  **SVR**                                                                                           
                                                                                                    
  A: n-3            822 ± 328                           644 ± 194     629 ± 228                     864 ± 376
                                                                                                    
  B: LCT            863 ± 217                           840 ± 274     884 ± 298                     932 ± 238
                                                                                                    
  **DO~2~**                                                                                         
                                                                                                    
  A: n-3            1074 ± 340                          1171 ± 406    1174 ± 372                    1066 ± 518
                                                                                                    
  B: LCT            966 ± 224                           1023 ± 330    936 ± 227                     856 ± 225
                                                                                                    
  **VO~2~/DO~2~**                                                                                   
                                                                                                    
  A: n-3            0.22 ± 0.04                         0.24 ± 0.05   0.23 ± 0.04                   0.25 ± 0.06
                                                                                                    
  B: LCT            0.26 ± 0.05                         0.25 ± 0.04   0.27 ± 0.03                   0.25 ± 0.04
                                                                                                    
  **Q~s~/Q~t~**                                                                                     
                                                                                                    
  A: n-3            33 ± 10                             31 ± 8        33 ± 11                       28 ± 7
                                                                                                    
  B: LCT            28 ± 11                             27 ± 6        25 ± 8                        25 ± 9
                                                                                                    
  **BT**                                                                                            
                                                                                                    
  A: n-3            38.1 ± 1                            38 ± 0.9      38.1 ± 0.8                    37.6 ± 1.2
                                                                                                    
  B: LCT            37.6 ± 0.4                          37.5 ± 0.6    37.6 ± 0.4                    37.1 ± 1

HR: heart rate, CO: cardiac output, SAP: systolic artery pressure, MPAP: mean pulmonary artery pressure, PW: pulmonary artery occlusion pressure, PVR: pulmonary vascular resistances, SVR: systemic vascular resistances DO~2~: oxygen delivery, Q~s~/Q~t~: venous admixture ratio, BT: body temperature.

\* p \< 0.05 between baseline groups

###### 

Respiratory parameters

                      **T-0 h (baseline, preinfusion)**   **T-6 h**     **T-12 h (final infusion)**   **T-18 (6 h postinfusion)**
  ------------------- ----------------------------------- ------------- ----------------------------- -----------------------------
  **PaO~2~/FiO~2~**                                                                                   
                                                                                                      
  A: n-3              137 ± 35                            143 ± 44      161 ± 87                      162 ± 59
                                                                                                      
  B: LCT              158 ± 43                            158 ± 47      184 ± 84                      192 ± 66
                                                                                                      
  **pH**                                                                                              
                                                                                                      
  A: n-3              7.42 ± 0.07                         7.41 ± 0.07   7.38 ± 0.06                   7.41 ± 0.07
                                                                                                      
  B: LCT              7.40 ± 0.07                         7.41 ± 0.06   7.40 ± 0.06                   7.41 ± 0.1
                                                                                                      
  **PaO~2~**                                                                                          
                                                                                                      
  A: n-3              90 ± 25                             99 ± 17       127 ± 85                      106 ± 30
                                                                                                      
  B: LCT              101 ± 32                            99 ± 31       113 ± 59                      122 ± 42
                                                                                                      
  **PaCO~2~**                                                                                         
                                                                                                      
  A: n-3              42 ± 2.3                            41.2 ± 4.9    44.6 ± 4.7                    43.8 ± 5
                                                                                                      
  B: LCT              40.5 ± 7.6                          41.9 ± 8      41.3 ± 5                      40.5 ± 6
                                                                                                      
  **ST BIC**                                                                                          
                                                                                                      
  A: n-3              26.6 ± 4.5                          25.5 ± 4.7    25.6 ± 4.1                    26.6 ± 3.4
                                                                                                      
  B: LCT              24.5 ± 4                            25.9 ± 5.4    25 ± 3.1                      25.5 ± 5.2
                                                                                                      
  **BE**                                                                                              
                                                                                                      
  A: n-3              2.4 ± 4.6                           0.9 ± 4.8     0.6 ± 4.5                     1.9 ± 4.4
                                                                                                      
  B: LCT              0.1 ± 4.4                           1.2 ± 5       0.3 ± 4                       0.9 ± 5.5

BE: base excess, ST BIC: standard bicarbonate.

Effect on gas exchange
----------------------

After the administration of lipid emulsions, no significant modifications, intragroup or intergroup, in gas exchange or respiratory variables were observed (table [3](#T3){ref-type="table"})

Effect on hemodynamics
----------------------

No significant differences were observed in either blood pressure or any other parameter studied during the administration of the lipid emulsions. Comparison of the changes between the two groups only yielded significant findings for pulmonary capillary pressure, which was lower at the end of emulsion infusion in group A, which received the lipid emulsion enriched with n-3 fatty acids. The fluid balance and medications used were similar in both groups (table [2](#T2){ref-type="table"}).

Discussion
==========

The results of the present study suggest that none of the lipid emulsions administered at the rate and for the duration studied here produced gas exchange or hemodynamic disturbances in patients with ARDS. This suggests that the emulsions were clinically safe under these conditions. The changes in gas exchange induced by lipid emulsions in patients with ARDS depend on various factors such as the rate of administration and duration, composition of the lipid emulsions (as precursors of prostanoid synthesis), and the characteristics of the study populations (tables [4a](#T4){ref-type="table"}, and [4b](#T4){ref-type="table"}).

###### 

Cardiopulmonary effects of LCT and MCT/LCT in humans

  ----------------------- -------------- ------------------- ------------------------ -------------------------------------------
                                                                                      

  **A (LCT)**                                                                         

                                                                                      

  **Author**              **Emulsion**   **Infusion rate**   **Patients**             **Results**

                                                                                      

  Venus\[[@B11]\]         20% LCT        100 g/10 h          Sepsis\                  ↑ MPAP, ↑ Q~s~/Q~t~
                                                             Non-sepsis               

                                                                                      

  Venus\[[@B12]\]         20% LCT        100 g/8 h           ARDS                     ↓ PaO~2~/FiO~2~\
                                                                                      ↑ MPAP, ↑ Q~s~/Q~t~, ↑ PVR

                                                                                      

  Hwang\[[@B8]\]          10% LCT        50 g/4 h            Healthy\                 ↓ Q~s~/Q~t~, ↑ PaO~2~/FiO~2~\
                                                             ARDS\                    ↑ Q~s~/Q~t~, ↓ PaO~2~/FiO~2~\
                                                             Pneumonia\               No changes\
                                                             COPD                     No changes

                                                                                      

  Mathru\[[@B7]\]         20% LCT        100 g/10 h\         ARDS\                    ↑ Q~s~/Q~t~, =MPAP\
                                         100 g/5 h           ARDS                     =Q~s~/Q~t~, ↑ MPAP

                                                                                      

                                                                                      

  **B (MCT/LCT)**                                                                     

                                                                                      

                                                                                      

  Radermacher\[[@B13]\]   20% MCT/LCT    50 g/4 h            Sepsis                   No changes

                                                                                      

  Fiaccadori\[[@B14]\]    20% MCT/LCT    3.3 mg/kg min       Heart surgery            No changes

                                                                                      

  Masclans\[[@B17]\]      20% LCT\       2 mg/kg/min 12 h\   ARDS\                    ↑ CO\
                          20% MCT/LCT    2 mg/kg/min 12 h    ARDS                     No changes

                                                                                      

  Smyrniotis\[[@B18]\]    20% LCT\       50% non-prot cal    Pancreatitis with ARDS   ↑ MPAP, ↑ Q~s~/Q~t~, and ↓ PaO~2~/FiO~2~\
                          20% MCT/LCT                                                 ↑ VO~2~, ↑ CO

                                                                                      

  Chassard\[[@B19]\]      20% LCT\       3 mg/kg/min 8 h\    Sepsis                   No changes\
                          20% MCT/LCT    3 mg/Kg/min 8 h                              ↑ VO~2~

                                                                                      

  Faucher\[[@B20]\]       20% LCT\       1 ml/kg/h 6 h\      ARDS                     ↑ PaO~2~/FiO~2~, ↑ DO~2~
                          20% MCT/LCT    1 ml/kg/h 6 h                                

                                                                                      

  Lekka\[[@B16]\]         20% MCT/LCT\                       ARDS: lipids\            ↓ PaO~2~/FiO~2~, ↓ Comp, ↓ PVR
                          Placebo                            Placebo                  
  ----------------------- -------------- ------------------- ------------------------ -------------------------------------------

VO~2~: oxygen consumption, Comp: compliance.

Analysis of the cardiopulmonary effects of lipid emulsions in our previous studies and the literature yields contradictory findings. In relation to the administration of LCT enriched emulsions; in healthy adults the administration of 4 hours infusion of Intralipid was followed by a significant increase in systolic and diastolic blood pressure as well as heart rate\[[@B10]\]. 500 ml of LCT 20% infusion increases pulmonary artery pressure and venous admixture in critically ill patients. The changes observed were temporary and coincidental with serum lipemia\[[@B11]\]. The same authors, in ARDS patients observed that an infusion of 20% LCT at 3.0 ± 0.3 mg/kg/min was followed by a transitory reduction in PaO~2~/FIO~2~, and an increase in MPAP, pulmonary vascular resistance and pulmonary venous admixture\[[@B12]\]. In different type of patients, the administration of 500 ml of LCT 10% in 4 h resulted in a reduction of the PaO~2~/FiO~2~ratio and increased P(A-a)O~2~and intrapulmonary shunting only in patients with ARDS\[[@B8]\]. Slow infusion of an LCT 20% emulsion (500 ml in 10 h) to patients with pulmonary injury increased intrapulmonary shunting, possibly by increasing the production of endogenous vasodilators, while rapid administration of the emulsion (500 ml in 5 h) increased MPAP possibly due to synthesis of endogenous vasoconstrictors\[[@B7]\].

Athough, theorically, the administration of emulsions enriched with MCT/LCT should have a neutral effect due to the few amount of PUFAs, the review of the literature was not concordant. In septic patients MCT/LCT administration did not induce any alterations in pulmonary hemodynamics, gas exchange, or distribution of ventilation/perfusion\[[@B13]\]. No hemodynamic neither respiratory modifications were observed in patients immediately after valvular surgery\[[@B14]\] or in critically ill patients with mechanical ventilation\[[@B15]\]. In contrast, deterioration of oxygenation, compliance, and pulmonary vascular resistance was observed after administering MCT/LCT to patients with ARDS\[[@B16]\]. Our group analyzed the gas exchange and pulmonary haemodynamic responses to LCT or MCT/LCT in ARDS patients. LCT infusion was followed by an increment in oxygen consumption without alterations in arterial oxygenation probably by the benefficial effect of the increase in cardiac output observed\[[@B17]\]. Also in patients with ARDS, while LCT infusion was followed by an increase in MPAP, and in pulmonary venous admixture, and a decrease in arterial PaO~2~, MCT/LCT infusion produced an increase in oxygen consumption, cardiac output and CO~2~production\[[@B18]\]. In critically ill patients with mechanical ventilation, the infusion of MCT/LCT vs LCT was accompanied by increased oxygen consumption and minute ventilation\[[@B19]\]. A benefit in oxygenation and increased cardiac output was demonstrated in patients with ARDS treated with MCT/LCT lipid emulsions compared to LCT\[[@B20]\]. From the revision of different data available using LCT, MCT/LCT fat emulsions we observed contradictory effects on pulmonary and hemodynamic variables; probably due to the different pathologic situations, and the amount and rate of lipid emulsions administered.

It seems that soy bean lipid emulsions represent an imbalanced fatty acid supply, with an overabundance of n-6 PUFAs. Emulsions that include MCT and fish oil as a partial replacement for soy bean are now available, and evidence to data is that these emulsions offer some advantages over the use of soy bean alone. At the neutral metabolic effects of MCTs they added the beneficial properties of n-3 fatty acids, with diminished circulating concentrations of inflammatory eicosanoids \[[@B21]-[@B23]\]. Several studies in surgical and septic patients promotes the use of omega-3 lipids in these clinical situations, however few data from randomized controlled trials are available \[[@B24],[@B25]\]. In patients with ARDS, our group showed that intravenous administration of an n-3 enriched lipid emulsion was accompanied by the synthesis of a smaller amount of proinflammatory mediators compared to LCT 100% emulsion\[[@B26]\].

Conclusion
==========

In our series of patients with ARDS, no significant changes were observed in hemodynamics or gas exchange, which demonstrated the safety of n-3 enriched lipid emulsions in these critical patients. The absence of theorically expected changes related to modifications observed in the eicosanoid profile may be due to the short duration of treatment with lipid infusion. However, now that it has been demonstrated that the n-3 enriched emulsion is safe, it can be used for studies in patients with ARDS who require PN. More prolonged use may reveal improvements in the clinical evolution of this group of patients, who traditionally bear a heavy morbidity and mortality.

Key messages
============

• Lipid n-3 enriched emulsions are safe in short term treatments with ARDS patients.

• Despite theorical benefits in eicosanoid profile, the absence of clinical benefit could be due to the short treatment duration. Further studies are needed with longer infusion treatments.
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